Literature DB >> 12055813

Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru.

Jave Ortiz Juan1, Nicholas Lopez Chegne, Gilles Gargala, Loic Favennec.   

Abstract

Three randomized clinical studies were conducted in 2000 to evaluate the efficacy of nitazoxanide paediatric suspension compared to albendazole in the treatment of ascariasis and trichuriasis and praziquantel in the treatment of hymenolepiasis in children from Cajamarca, Peru. Nitazoxanide was administered at a dose of 100 mg (age 1-3 years) or 200 mg (age 4-11 years) twice daily for 3 days, albendazole as a 400-mg single dose and praziquantel as a 25-mg/kg single dose. Post-treatment parasitological examinations were carried out on 3 faecal samples, each collected on a different day between 21 and 30 days following initiation of treatment. Nitazoxanide cured 89% (25/28), 89% (16/18) and 82% (32/39) of the cases of ascariasis, trichuriasis and hymenolepiasis respectively compared with 91% (32/35), 58% (11/19) and 96% (47/49) for the comparator drugs. Each of the drugs produced egg reduction rates in excess of 98%. There were no significant adverse events or abnormalities in haematology or clinical chemistry values or urinalysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055813     DOI: 10.1016/s0035-9203(02)90301-9

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  22 in total

1.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

2.  Biliary parasites: diagnostic and therapeutic strategies.

Authors:  Niraj Khandelwal; Joanna Shaw; Mamta K Jain
Journal:  Curr Treat Options Gastroenterol       Date:  2008-04

3.  Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Paul S Hoffman; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2010-05-18       Impact factor: 2.823

4.  Nitazoxanide: nematicidal mode of action and drug combination studies.

Authors:  Vishal S Somvanshi; Brian L Ellis; Yan Hu; Raffi V Aroian
Journal:  Mol Biochem Parasitol       Date:  2014-01-08       Impact factor: 1.759

5.  Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain.

Authors:  P Ripani; J Delp; K Bode; M E Delgado; L Dietrich; V M Betzler; N Yan; G von Scheven; T U Mayer; M Leist; T Brunner
Journal:  Oncogene       Date:  2019-12-16       Impact factor: 9.867

Review 6.  Human gastrointestinal nematode infections: are new control methods required?

Authors:  Gillian Stepek; David J Buttle; Ian R Duce; Jerzy M Behnke
Journal:  Int J Exp Pathol       Date:  2006-10       Impact factor: 1.925

Review 7.  A review and meta-analysis of the impact of intestinal worms on child growth and nutrition.

Authors:  Andrew Hall; Gillian Hewitt; Veronica Tuffrey; Nilanthi de Silva
Journal:  Matern Child Nutr       Date:  2008-04       Impact factor: 3.092

8.  Nematocidal activity of nitazoxanide in laboratory models.

Authors:  F Fonseca-Salamanca; M M Martínez-Grueiro; A R Martínez-Fernández
Journal:  Parasitol Res       Date:  2003-09-12       Impact factor: 2.289

Review 9.  Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.

Authors:  Vanessa R Anderson; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond.

Authors:  David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.